Operating
Royalty Pharma·Cash Flow Statement·9 metrics
Breakdown
| Metric | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Cash collections from financial royalty assets | $669.4M | $791.6M | $777.5M | $829.7M | $726.5M | $882.4M | $916.1M | $915.6M |
| Net cash from operating activities | $658.2M | $703.6M | $742.5M | $596.1M | $364M | $702.6M | $827.1M | $718.2M |
| Payments For Operating Costs And Professional Services | $48.1M | $55.2M | $72.4M | $101.7M | $94M | $34.2M | $58.2M | $36.3M |
| Other royalty cash collections | $23.2M | $29.8M | $29.5M | $31.8M | $24.1M | $29.1M | $29.1M | $33.6M |
| Payments For Development Stage Funding | — | — | $500K | $50.5M | — | — | $50.5M | $25.5M |
| Payments for Employee Equity Performance Awards | — | $0 | $0 | $0 | $173K | $1.7M | $9.1M | $9.7M |
| Cash collections from intangible royalty assets | $486K | $390K | $227K | $177K | $240K | $264K | $39K | $3.8M |
| Distributions from equity method investments | — | — | — | $13.4M | — | — | — | $3.7M |
| Distributions of earnings from equity method investees | — | — | — | $13.4M | — | — | — | $3.7M |